Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | The role of vaccines in AML

David Avigan • 26 Aug 2022
IMS 2022
Acute Myeloid Leukemia Leukemia CAR-T Vaccines

David Avigan, MD, Harvard Medical School, Boston, MA, comments on the challenge of finding a target for CAR-T therapy in acute myeloid leukemia (AML), highlighting the potential role of vaccines in this disease. Dr Avigan explains that it appears that vaccines may have a role in preventing relapse rather than attempting to bring patients into remission. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from David Avigan

Overcoming challenges in TCR mapping for personalized immunotherapy in multiple myeloma
1:09
Overcoming challenges in TCR mapping for personalized immunotherapy in multiple myeloma
David Avigan • 23 Sep 2026
Identifying tumor-reactive T-cell clones to guide personalized immunotherapy in multiple myeloma
1:25
Identifying tumor-reactive T-cell clones to guide personalized immunotherapy in multiple myeloma
David Avigan • 23 Sep 2026
Single-cell antigen & TCR mapping to investigate tumor-reactive T-cell responses in multiple myeloma
3:08
Single-cell antigen & TCR mapping to investigate tumor-reactive T-cell responses in multiple myeloma
David Avigan • 23 Sep 2026
Impact of dendritic cell fusion vaccine on the microenvironment and outcomes in multiple myeloma
2:26
Impact of dendritic cell fusion vaccine on the microenvironment and outcomes in multiple myeloma
David Avigan • 26 Aug 2022

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals